How is prostate cancer detected?

Written by Zhou Zi Hua

Oncology

Updated on September 21, 2024

00:00

00:00

Digital rectal examination combined with PSA testing is currently recognized as the best screening method for the early detection of prostate cancer. Currently, systematic prostate needle biopsy is the most reliable method for diagnosing prostate cancer. In addition, prostate cancer MRI plays an important role in clinical staging. There is also a whole-body nuclear bone marrow scan that can detect the most common metastatic sites of prostate cancer, including bone metastases.

Other Voices

home-news-image

Written by Zhou Zi Hua

Oncology

57sec

home-news-image

Commonly used drugs for endocrine treatment of prostate cancer

The purpose of endocrine therapy for prostate cancer is to reduce the concentration of androgens in the body, inhibit the synthesis of androgens originating from the adrenal glands, inhibit the conversion of testosterone to dihydrotestosterone, or block the binding of androgens to their receptors, thereby inhibiting or controlling the growth of prostate cancer cells. The medications include a luteinizing hormone-releasing hormone analogue, with representative drugs being leuprorelin, goserelin, and triptorelin. There is also an androgen-blocking drug, including steroidal drugs with representative drugs like cyproterone acetate, and non-steroidal drugs with representative drugs like bicalutamide and flutamide. Additionally, there are estrogens, with the most common being diethylstilbestrol.

home-news-image

Written by Zhou Zi Hua

Oncology

34sec

home-news-image

How long can one live after prostate cancer has spread to the bones?

Bone metastasis is the most common site of metastasis for prostate cancer. If a patient with prostate cancer develops bone metastasis, it means that the cancer is no longer in its early stages and has progressed to a more advanced stage. However, unlike other cancers with a higher degree of malignancy, if the tumor is highly sensitive to hormone therapy, with standardized treatment, the patient's survival time can be significantly extended.

home-news-image

Written by Liu Liang

Oncology

59sec

home-news-image

Can prostate cancer be cured?

Prostate cancer, whether it can be cured or not, depends on the specific analysis of the patient with prostate cancer. If it is an early-stage patient, meaning there is no metastasis to distant organs, and it is assessed that radical surgery or radical radiotherapy can be performed, then these early-stage prostate cancer patients still have the hope of being cured through these treatment methods. However, for patients with advanced prostate cancer, such as those who are diagnosed with multiple bone metastases at the onset—a very common clinical occurrence, prostate cancer combined with bone metastasis is very common—these advanced-stage prostate cancer patients cannot be cured through treatment. The purpose of treatment is to alleviate the patient's pain and extend the patient's survival, but these advanced-stage patients cannot be cured.

home-news-image

Written by Zhou Zi Hua

Oncology

27sec

home-news-image

Late-stage prostate cancer with bone metastases: how long can one survive?

Bone metastasis is the most common site of metastasis for prostate cancer. If prostate cancer has metastasized to the bones, it means it is not in its early stages but has entered the advanced stages. However, this type of tumor is not like others with a higher degree of malignancy. If it has a good sensitivity to hormone therapy, after our standardized treatment, the survival time can still be quite long.

home-news-image

Written by Yan Chun

Oncology

1min 9sec

home-news-image

Will prostate cancer embryonic antigen rise?

Prostate cancer is a common malignant tumor in the male urinary system. In some patients with prostate issues, there may be an increase in the carcinoembryonic antigen index in blood tests, but not all patients will exhibit this marker increase. Most prostate cancer patients will show an increase in the prostate-specific antigen (PSA) in blood tests, or there may be abnormal ratios of free PSA to bound PSA. Carcinoembryonic antigen and prostate-specific antigen are tumor markers for prostate cancer, but they only provide auxiliary value for diagnosis and do have some evaluative value regarding the effectiveness of anti-tumor treatment. Additionally, they can serve as a monitor for the condition of prostate cancer. Clinically, to confirm a diagnosis of prostate cancer, it is necessary to rely on the results of pathological tissue obtained through biopsy.